MetaVia is trading at $1.41, up 5.44% pre-market, with no verified company-specific explanation identified for the move.
- A report of after-hours gains also cited no verified company-specific explanation.
- MetaVia announced an October 28 presentation of DA-1726 Phase 1 data at the November 4 Precision Liver Symposium; available sources do not establish it as the cause of this pre-market move.
- Nasdaq lists November 5 as an estimated earnings date, not a confirmed results release.